Gilead Sciences (Nasdaq: GILD) has published data at 96 weeks in two Phase III studies of Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) in treating HIV-1 in treatment-naive adults.
Genvoya was found to be statistically non-inferior to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate) based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated improved renal and bone laboratory parameters compared to Stribild.
Tenofovir alafenamide is a novel investigational nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a low dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze